Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Jackson, Mississippi 39216


Purpose:

This study will evaluate the overall remission rate of treatment with voreloxin Injection in patients at least 60 years of age with previously untreated AML


Study summary:

Other objectives of this study include: 1. Safety 2. Survival 3. Pharmacokinetics 4. Evaluate potential biomarkers


Criteria:

Inclusion Criteria: 1. At least 60 years of age and diagnosis of previously untreated AML (either de novo or from an antecedent hematologic disorder or therapy related AML) 2. At least 20% blasts by BM biopsy or aspirate 3. ECOG performance status of 0,1,or 2 4. Adequate cardiac, renal and liver function Exclusion Criteria: 1. Uncontrolled DIC 2. Active central nervous system involvement by AML 3. Requiring hemodialysis or peritoneal dialysis 4. Some prior history of heart attack or stroke (depending on how long ago the event occurred)


NCT ID:

NCT00607997


Primary Contact:

Study Director
Sunesis Medical Monitor, MD
Sunesis Pharmaceuticals


Backup Contact:

N/A


Location Contact:

Jackson, Mississippi 39216
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.